Literature DB >> 7528282

Identification, synthesis, and characterization of a unique class of N-methyl-D-aspartate antagonists. The 6,11-ethanobenzo[b]quinolizinium cation.

J P Mallamo1, W G Earley, V Kumar, C Subramanyam, J A Dority, M S Miller, D L DeHaven-Hudkins, B Ault, J L Herrmann, J S Dung.   

Abstract

A series of novel N-methyl-D-aspartate antagonists acting at the phencyclidine site has been identified. Compound 2 has a Ki = 8 +/- 1 nM (vs [3H]thienylcyclidine, [3H]TCP) as a mixture of enantiomers. Resolution and further testing indicate that (-)-2, Ki = 4 +/- 0.7 nM, is a potent and selective TCP site ligand with neuroprotective activity in cultured neurons in the presence of excitotoxic concentrations of NMDA (IC50 = 26 nM). Compound (-)-2 is > 1000-fold selective for the TCP site vs a panel of receptor types including opiate, adrenergic, serotonergic, dopamine, adenosine, dihydropyridine, and benzodiazepine and displays increased selectivity for the activated (open) NMDA receptor-ion channel complex vs PCP and MK801 as measured by patch recordings in cultured, voltage-clamped neurons. Highly enhanced "open-channel" selectivity leads to tentative classification of these ligands as uncompetitive vs NMDA. Ligands with these characteristics may enable deconvolution of the pharmacologic effects associated with typical noncompetitive NMDA antagonists. We report here on the identification, synthesis, and activity of compounds of this structural class.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528282     DOI: 10.1021/jm00052a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Structures, biomimetic synthesis, and anti-SARS-CoV-2 activity of two pairs of enantiomeric phenylpropanoid-conjugated protoberberine alkaloids from the rhizomes of Corydalis decumbens.

Authors:  Jing-Guang Lu; Yingwei Wang; Ming-Rong Yang; Cai-Yun Wang; Jieru Meng; Jiazheng Liu; Zifeng Yang; Kongsong Wu; Li-Ping Bai; Guo-Yuan Zhu; Zhi-Hong Jiang
Journal:  Arch Pharm Res       Date:  2022-09-19       Impact factor: 6.010

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.